Verismo Therapeutics

Verismo Therapeutics is developing a next-generation CAR T cell therapy platform, SynKIR™, which utilizes a multi-chain KIR-CAR design to overcome the limitations of traditional single-chain CARs in solid tumors. The platform, invented by founders with deep expertise in cell therapy including the inventors of Kymriah™, has shown promising preclinical efficacy and is now entering early clinical testing. The company's lead programs, SynKIR-110 and SynKIR-310, target solid tumor indications, representing a significant opportunity in a high-unmet-need area of oncology. Verismo is a private, pre-revenue company positioned at the forefront of innovating CAR T cell therapy for solid cancers.

SynKIR™ platform: a multi-chain KIR-CAR (Killer Immunoglobulin-like Receptor-based Chimeric Antigen Receptor) T cell therapy platform designed to mimic natural NK cell receptor signaling, aiming to reduce T cell exhaustion and improve persistence in solid tumors.

Verismo competes in a crowded and rapidly evolving field of next-generation CAR T and engineered cell therapies for solid tumors. Competitors include large pharma (e.g., Novartis, Gilead/Kite) and numerous biotechs developing armored CARs, logic-gated CARs, and TIL therapies. Verismo's differentiation is its specific focus on a multi-chain KIR-based receptor architecture.